Get Top Rated Stock Alerts Active Traders Depend On
Sign Up Today For FREE News Driven Alerts
San Diego, CA – August 4, 2020—Nascent Biotech, Inc (OTCQB: NBIO), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat cancers and viral infections, has participated in the recent expert panel discussion entitled “BCG: a therapeutic modality for COVID-19 and cancers” hosted by the Bioidea Group (https://bioidea.co/2020/07/13/bcg-covid-19/). The virtual session featured distinguished clinicians and scientists working on the TB / BCG vaccine for COVID-19 and cancer. The event was moderated by Dr Navpaul Singh, Chief Medical Consultant from Nascent Biotech, Inc and live streamed to social media platforms. Live stream recording is available on YouTube: https://www.youtube.com/watch?v=SumCzJOn0nc.
Manhattan BioSolutions, Inc. founder and CEO, Dr. Boris Shor, who also participated in the discussion, highlighted the recent collaboration agreement with Nascent Biotech and ongoing objectives between the two companies. Dr. Shor reasserted that Manhattan BioSolutions is focused on the discovery of the next-generation therapies for the treatment of cancer and inflammatory diseases, and that its unique oncology programs could also be applied towards the discovery of novel agents against COVID-19 to significantly impact the current and/or future viral outbreaks. The two companies signed the research agreement in May of this year and have since initiated a vaccine program for the potential prevention of COVID-19 or other viral infections. This effort will augment Nascent’s current development plans to investigate the utility of its monoclonal antibody Pritumumab for the treatment of COVID-19, as announced earlier in March.
Dr. Boris Shor reiterated “Manhattan BioSolutions has a longstanding commitment to advance the basic research of immunotherapies and we are excited to be working with Nascent Biotech on constructing a vaccine to prevent COVID-19 around the world. The latest literature revealed a correlation showing that countries with higher rates of Bacille Calmette-Guérin (BCG) vaccinations had lower peak mortality rates from COVID-19. These beneficial effect of BCG (TB vaccine) against viral infections are proposed to be mediated by the stimulation of innate immune mechanisms, also termed trained immunity. Clinical trials around the world are underway to investigate the protective effects of BCG against COVID-19. Our novel platform will be based on the recombinant BCG, genetically engineered to express selected SARS-CoV-2 proteins. The new design addresses major limitation of old-generation unmodified BCG to stimulate the human immune system broadly: a lack of specificity to SARS- CoV-2. Together, we will be in a strong position to advance the discovery and development of an innovative vaccination platform against coronaviruses.”
About Nascent Biotech
Nascent Biotech, Inc. (OTCQB: NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies (mAbs) for the treatment of incurable cancers such as brain and pancreas, as well as hard-to-treat cancers such as colon and lung. Nascent is also employing its mAbs as part of treatments for dangerous viral infections, such as COVID-19. Collectively, cancers and viral infections afflict and kill tens of millions worldwide each year. Nascent’s products are not commercially available. Our lead candidate, Pritumumab (PTB), is a fully-human mAb that will commence study in an FDA-approved Phase I clinical trial later this year for the treatment of primary and metastatic brain cancer, including glioblastoma and malignant astrocytoma. Development of PTB as a potential treatment for COVID-19 has been initiated. For more information, visit www.nascenbiotech.com.
About Manhattan BioSolutions
Manhattan BioSolutions, Inc is a privately held biotechnology company focused on the discovery and development of immunotherapies that target innate immunity for the treatment of cancer and inflammatory diseases. Manhattan BioSolutions leverages two technology platforms for drug discovery: a microbial based genetically engineered immune stimulator platform, and monoclonal antibodies against innate immune sensors that recognize pathogens or endogenous “danger signals” released as a result of tissue injury or inflammation.
Forward Looking Statement Safe Harbor:
Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
Contact:
Sean Carrick
President | CEO
Nascent Biotech, Inc.
6330 Nancy Ridge Dr
Suite 105 San Diego CA 92121
772.713.0541 Cell
sean.carrick@nascentbiotech.com Manhattan BioSolutions: Boris Shor, PhD ir@manhattanbiosolutions.com
Source: Nascent Biotech, Inc
San Diego, CA – July 28, 2020 – Nascent Biotech, Inc. (OTCQB.NBIO), announced today it has entered into a research collaboration with Syracuse University to further the development of Pritumumab, a unique monoclonal antibody that binds to cell-surface vimentin, for potential use in COVID-19 treatment.
Alison Patteson, an assistant professor of physics at Syracuse University, will test to see if Pritumumab has the potential to block SARS-CoV-2 (SARS2), the virus responsible for COVID-19, from entering cells. According to Patteson, research shows that SARS2 may be traveling into cells by way of a receptor known as cell-surface vimentin (CSV). This ia a protein found on the cell surface, similar to vimentin, which is a key internal structural protein present in many cell types. Vimentin is known for its cage-like structure which protects the cell against damage..
“Our hope is that when we treat cells with Pritumumab, it will bind to CSV, and effectively block the SARS2 virus from entering the cell,” says Patteson. “An antibody that could block the entry of SARS2 into the cell could be a monumental step in the fight against COVID-19.”
Patteson will test the hypothesis on mouse embryo fibroblast cells and lung airway epithelial cells to determine if the antibody will block the uptake of SARS2. Using a cell in which vimentin has been knocked out, the results will provide an important control of Pritumumab effects.
Nascent Biotech Chief Medical Officer over Viral Research, Dr. Navpaul Singh said, “This collaboration will determine if Pritumumab can effectively block SARS2 in an animal mouse model. It will also gauge Pritumumab’s ability to bind vimentin in a live model.”
About Nascent Biotech, Inc.:
Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.
Safe Harbor:
Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
For further information, please contact:
Sean Carrick
President CEO
Nascent Biotech, Inc
6330 Nancy Ridge Dr
Suite 105
San Diego CA 92121
(612) 961-5656
Sean.carrick@nascentbiotech.com
Source: Nascent Biotech, Inc
San Diego, CA – June 17, 2020 – Nascent Biotech, Inc. (OTCQB: NBIO), today announced after receiving early In-Vitro study results Pritumumab, (PTB), will be advanced to laboratory-based animal studies. Nascent founder and Advisory Board Chairman Dr. Mark Glassy commented, “the laboratory results were consistent with our Brain Cancer invitro studies and this is the next step in investigational development of PTB as potential use with COVID-19 and related Viral Infections.”
An article in The Journal of Biological Medicine (Yu et al. Journal of Biomedical Science (2016) 23:14 DOI 10.1186/s12929-016-0234-7) specifically mentioned cell surface vimentin as a potential target in the treatment of conditions related to the Coronavirus which was instrumental in Nascent’s investigation into Viral Infections.
Nascent’s Management is continuing development in Viral Infections along with opening the Phase I Brain Cancer Clinical Trial at Hoag Family Cancer Institute and Pickup Family Neurosciences Institute Presbyterian.
About Nascent Biotech Inc
Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.
Safe Harbor:
Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Sean Carrick
CEO Nascent Biotech, Inc
6330 Nancy Ridge Dr
Suite 105
San Diego CA 92121
(612) 961-5656
Sean.carrick@nascentbiotech.com
Source: Nascent Biotech, Inc
San Diego, CA – June 03, 2020— Nascent Biotech, Inc (OTCQB: NBIO) (the “Company” or “Nascent”) is pleased to provide a corporate update and summary with a recent interview the Company’s CEO, Sean Carrick, presented on SNN Network. The complete interview may be seen on the SNN Network at https://www.youtube.com/watch?v=bq-iWU9Ss_E&t=93s.
Mr. Carrick indicates,” As the Company moves forward with execution of its active 2020 agenda, key strategic initiatives will bring increased shareholder value to the Company. These include Nascent’s landmark Phase 1 studies on its Pritumumab (PTB) antibody for brain cancer, COVID-19 in vitro studies, and the virus vaccine program.”
During the interview Mr. Carrick updated the audience on a series milestones completed by the Company including:
- The Company has performed all necessary U.S. preclinical work and developed successful manufacturing techniques for PTB and is now ready to begin Phase 1 Brain Cancer studies.
- Nascent is ahead of the curve as the Company’s PTB monoclonal Antibody due to its clear clinical and regulatory pathway for the treatment of deadly brain cancers with PTB.
- Studies published by independent third parties, including an article in The Journal of Biological Medicine (Yu et al. Journal of Biomedical Science (2016) 23:14 DOI 10.1186/s12929-016-0234-7) identifying a means of infection by the Coronavirus’ use of cell surface vimentin for cell entry, has launched Nascent’s timely research. Specifically, the article mentioned cell surface vimentin as a potential target in the treatment of conditions related to the Coronavirus. The Company’s PTB antibody targets the cell surface vimentin structure, which may serve to effectively block the virus ability to enter the cells.
- The Company’s response to COVID-19, indicating that Nascent is awaiting results from in vitro testing prior to the next step in its study of PTB and its use against viruses.
- Collaboration with Manhattan BioSolutions Inc. in developing vaccines to be used against viruses around the world. The vaccine program employs a recombinant Bacillus Calmette-Guerin (rBCG), genetically engineered to express selected SARS-CoV-2 proteins. Based on preclinical experience with rBCG candidates for oncology indications and its safe track record as a tuberculosis vaccine, Nascent has the reason to believe that rBCG based vaccine against SARS-CoV-2 may be possible to develop.
- Nascent expects to apply for grants based on the outcomes of in vitro studies and confirms that the company has requested a pre-IND meeting with the FDA to accelerate trials for the SARS-CoV-2 indications.
About Nascent Biotech
Nascent Biotech, Inc. (OTCQB: NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies to be used in the treatment of various cancers and viral infections, helping millions of people worldwide. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com. Our lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) that will be studied in Phase I clinical trials for the treatment of Brain Cancer. Development for PTB as a treatment for COVID-19 is being researched .
Forward Looking Statement
Safe Harbor:
Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contact:
Sean Carrick
President | CEO
Nascent Biotech, Inc.
772.713.0541
sean.carrick@nascentbiotech.com
Source: Nascent Biotech, Inc.
San Diego, CA – May 27, 2020— Nascent Biotech, Inc (OTCQB: NBIO) (the “Company” or “Nascent”) is pleased to announce that the Company will soon begin Phase 1 clinical trials for a treatment of Brain Cancer, including, glioblastoma (GBM), the deadliest form of brain cancer.
The study will employ Nascent’s monoclonal, antibody, Pritumumab (“PTB”) and will be conducted in collaboration with a Southern CA Cancer Center as noted in their release which can be viewed at https://www.nascentbiotech.com/hoag-is-first-in-nation-to-test-innovative-antibody-brain-cancer-drug/
Nascent’s lead therapeutic asset, PTB, is a natural human antibody that works by binding to ectodomain vimentin (EDV), a protein expressed on the surface of epithelial cancers. The PTB antibody is used as a targeted immunotherapy, which unlike chemotherapy, targets only the cancer cells without damaging healthy cells.
Because EDV is found in a variety of cancers, these important clinical trials of PTB could have implications for a broad range of more common cancers, such as breast, colon and lung. The current Phase 1 trials have been uniquely designed to ultimately treat a variety of brain cancers from gliomas and other primary brain tumors to brain metastases and leptomeningeal cancers arising from breast, lung and other solid tumors.
Sean Carrick, CEO of Nascent Biotech, states, “Nascent is committed to opening this trial and delivering this promising treatment to patients afflicted with this devastating disease.“
For more information on the research studies and clinical trials, visit www.clinicaltrials.gov.
About Nascent Biotech
Nascent Biotech, Inc. (OTCQB: NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies to be used in the treatment of various cancers and viral infections, helping millions of people worldwide. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com. Our lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) that will be studied in Phase I clinical trials for the treatment of Brain Cancer. Development for PTB as a treatment for COVID-19 has been initiated.
Forward Looking Statement
Safe Harbor:
Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contact:
Sean Carrick
President | CEO
Nascent Biotech, Inc.
772.713.0541
sean.carrick@nascentbiotech.com
Source: Nascent Biotech, Inc.
San Diego, CA – May 12, 2020 – Nascent Biotech, Inc (OTCQB: NBIO), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat cancers and viral infections, and Manhattan BioSolutions, Inc., a biotechnology company focused on the discovery of the next-generation therapies for the treatment of cancer and inflammatory diseases, today announced they have entered into a Research Collaboration Agreement to initiate a vaccine program for the potential prevention of COVID-19 or other viral infections. This effort will augment Nascent’s current development plants to investigate the utility of Pritumumab for the treatment of COVID-19 that was announced earlier in March.
Dr. Boris Shor, Chief Executive Officer, Manhattan BioSolutions, commented, “Manhattan BioSolutions has a longstanding commitment to advance the basic research of immunotherapies and we are excited to be working with Nascent Biotech on constructing a vaccine to prevent COVID-19 around the world. Our novel platform will be based on the recombinant Mycobacterium Bovis Bacillus Calmette-Guerin (rBCG), genetically engineered to express selected SARS-CoV-2 proteins. BCG is a live non-pathogenic bacterium that stimulates diverse innate and adaptive immune responses and is well-known for its long safety track record as a tuberculosis vaccine. Our experience with the rBCG candidates initially constructed for oncology indications we expect that rBCG against SARS-CoV-2 will be possible to develop. Together, we will be in a strong position to advance the discovery and development of an innovative vaccination platform against coronaviruses.”
BCG is a well-validated treatment modality used for early-stage bladder cancer as well as the vaccine against tuberculosis. BCG vaccination has been also shown to produce positive “heterologous” immune effects leading to improved response against other infections. Its utility for the treatment or prevention of other diseases is only beginning to emerge. If successful it will ensure that people across the world, especially in emerging countries, will be protected from COVID-19 and other emerging health threats.
Nascent’s Scientific Advisory Board Chair, Dr. Mark Glassy, said, “This collaboration strengthens the infectious disease business platform and provides Nascent with two strong disease research platforms.”
“We go into this agreement with heightened optimism that we can build shareholder value while researching a treatment platform for COVID-19 and other devastating viral infections. We will soon begin a human clinical study for Brain Cancer with Pritumumab while expanding research through Manhattan BioSolutions into COVID-19,” said Nascent CEO Sean Carrick.
Under the terms of the agreement, Manhattan BioSolutions will receive up to $200,000, consisting of $100,000 initial payment through an equity transaction to advance the research and development of their recombinant BCG vaccine for the potential prevention of COVID-19 or other emerging coronavirus infections.
About Nascent Biotech
Nascent Biotech, Inc. (OTCQB: NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies to be used in the treatment of various cancers and viral infections helping millions of people worldwide. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com. Our lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) will be studied in Phase I clinical trial later this year for the treatment of Brain Cancer. Development for PTB as a treatment for COVID-19 has been initiated. For more information, visit www.nascentbiotech.com.
About Manhattan BioSolutions
Manhattan BioSolutions, Inc (MBS) is a privately held biotechnology company focused on the discovery and development of immunotherapies that target innate immunity for the treatment of cancer and inflammatory diseases. MBS leverages two technology platforms for drug discovery: microbial based genetically engineered immune stimulator platform, and monoclonal antibodies against innate immune sensors that recognize pathogens or endogenous “danger signals” released as a result of tissue injury or inflammation.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
Forward Looking Statement
Safe Harbor:
Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contact:
Sean Carrick
President | CEO
Nascent Biotech, Inc.
6330 Nancy Ridge Dr.
Suite 105
San Diego CA 92121
772.713.0541 Cell
sean.carrick@nascentbiotech.com
Source: Nascent Biotech, Inc
About Nascent Biotech
Delivering human antibodies for the treatment of cancer
Nascent Biotech is a California-based company focused on the development and delivery of human antibodies and cytokine responses for the treatment of cancer.
The innate ability of the intelligence of the natural human immune system to generate a cancer specific response combined with Nascent Biotech’s technical skills opens the door for immunologically based therapeutics for human cancer.
Nascent Biotech is using and developing human antibodies and cytokine responses obtained from the innate natural human immune response as a drug discovery platform for identifying new antibodies and antigens for commercialization.
Our insight into the natural human immune response defines important targets for therapeutic intervention thus enabling the rapid development of new classes of safe, non-toxic, and specific biological drugs for use in the clinic.
The company’s technology portfolio is based upon the natural human immune system, uniquely utilizing the immune system’s innate capabilities and selectivity to produce effective immune boosting and regulation biomolecules.
In our bodies, the natural immune response to harmful agents is both oligoclonal and oligocelluar; that is, several different antibodies and cell types are generated to attach a particular disease agent.
Use of a single monoclonal antibody (mAB), or monotherapy, to treat a disease – the approach employed by most pharmaceutical / biotechnology companies – may not be optimal and is certainly not the preferred natural approach.
Nascent Biotech’s approach to treatment of disease is to “mimic” the body’s natural antibody and cellular reponses by identifying and combining antibodies and natural cytokines into a single therapy for more effective disease treatment.
Nascent Biotech believes that by combining specifically selected biomolecules into a potent “cocktail”, one can create an efficient, multi-targetted attack against disease. Applications of this technology span cancer, metabolic disorders and infectious disease indications.
PRODUCTS
>> PRITUMUMAB
Nascent Biotech’s lead product, Pritumumab, a natural human antibody.
Pritumumab is a fully natural human IgG antibody that was derived using proprietary technology from a B-cell isolated from a tumor draining lymph node of a patient with cervical cancer.
The recognized target is ecto-domain vimentin that is expressed on the cell surface of a variety of adenocarcinomas, including brain cancers and melanoma, but not expressed by normal tissues and cells.
>> CLNH5
Nascent Biotech has been awarded 4 patents on CLNH5 from the United States Patent Office: 4618577; 6051229; 6051387; 6090924.
>> MULTIPHARM
MultiPharm™ is a platform technology proprietary to Nascent Biotech that may have additive and synergistic effects not only for cancer therapy but also diabetes, autoimmunity, and transplantation.
MultiPharm™ uses multiple agents (antibodies and/or cytokines).
MANAGEMENT
SEAN CARRICK
CHIEF EXECUTIVE OFFICER
Sean Carrick brings to Nascent an extensive track record of success with a career that spans more than 30 years of building and leading successful Life Science Companies in large, mid-cap and venture-backed stages. In addition, Mr. Carrick holds a BS Degree in Economics and Business Administration from Duquesne University and has completed several strategic leadership programs.
BRANDON J. PRICE, PHD
SENIOR VICE PRESIDENT, BUSINESS DEVELOPMENT
Dr. Price has more than 30 years in the biopharmaceutical industry. Recently he co-founded Biogenin, a Mexican company that licenses, develops and registers human and veterinary products (pharmaceuticals, diagnostics and medical devices) for Latin American markets. Dr. Price has been CEO of four biotechnology start-ups (plant transgenic expression systems, stem cell therapies, chemical cancer drugs, synthetic vaccines), and has held senior management positions at Cardinal Health and Ortho Diagnostic Systems (a Johnson & Johnson company). In addition, he co-founded the Institute for Cell Analysis at the University of Miami (FL), and the International Center for Entrepreneurial Excellence at the University of Guadalajara. He has served as Board Chair of the Virginia Biotechnology Association, Maryland’s counterpart, MdBIO, and was named 2001 Biotechnology Leader of the Year in Virginia. He currently sits on the Boards of four companies, and chairs the Advisory Board for the Professional Science Management Program in Bioinformatics at Virginia Commonwealth University (Richmond, VA). Presently, he is Visiting Professor at the University of Guadalajara School of Business where he teaches the course “Entrepreneurism and Business Planning”. He holds the B.S. and Ph.D. degrees in Biophysics from the University of Michigan in Ann Arbor and is the author of more than 50 articles in the scientific and business literature.
LOWELL HOLDEN
CHIEF FINANCIAL OFFICER
Lowell Holden has been the CFO and Chief Accounting Officer of the Company since May 2014. Since 1983, Mr. Holden has owned and operated his own consulting firm, LS Enterprises, Inc., which provides business consulting, accounting and other services to businesses. Mr. Holden has a broad range of business experience including managing, securing financing, structuring of transactions, and is experienced and knowledgeable in managing relationships with customers, financing institutions and stockholders. Mr. Holden also has a background in assisting companies in fulfilling their financial auditing and SEC reporting requirements. Mr. Lowell Holden has a Bachelor’s of Science degree from Iowa State University.
SOURCE: https://www.nascentbiotech.com/
Disclaimer
FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated forty eight hundred dollars for Nascent Biotech, Inc. current news coverage by a non-affiliated third party. FNMG HOLDS NO SHARES OF Nascent Biotech, Inc.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
Sign Up & Get FREE News Alerts From FNM Today!